The Greek medical cannabis industry is experiencing rapid growth, with Curity Pharma emerging as a key player in its evolution. On March 4, 2025, Curity Pharma announced that it had secured its operating license from Greek regulatory authorities. This milestone grants the company permission to commence full-scale operations at its state-of-the-art, vertically integrated medical cannabis facility.
Curity Pharma: A New Powerhouse in Greek Medical Cannabis
Curity Pharma’s facility, located in the Larissa Industrial Park, spans a total area of 67,000 square meters. The site includes a 5,000-square-meter cultivation greenhouse and a 1,800-square-meter production facility. With this license, Curity Pharma is set to contribute significantly to Greece’s expanding medical cannabis market.
The company joins an industry that has seen substantial regulatory advancements in recent years. Greece first legalized medical cannabis in 2017 by rescheduling it from Schedule A to Schedule D. In 2018, the government lifted the ban on cultivation and production, paving the way for companies like Curity Pharma to enter the market. By 2020, the first medical cannabis cultivation and production licenses were issued, solidifying Greece’s intent to become a competitive player in the European cannabis sector.
A Rapidly Evolving Market
The Greek medical cannabis market took a significant step forward in February 2024 when Tikun Olam Europe became the first company to provide prescription-based medical cannabis products in the country. Just months later, in November 2024, Greece celebrated its first-ever medical cannabis export, marking a major achievement for the country’s international trade aspirations.
According to Dimitris Athanasiadis, an industry analyst, the Greek medical cannabis market is poised for rapid growth due to increasing patient demand and favorable regulatory changes. The European medical cannabis market is projected to be worth billions in the coming years, and Greece’s ideal climate and strategic location position it as a potential leader in the industry.
Economic and Industry Impact
The economic impact of Greece’s burgeoning medical cannabis industry is expected to be substantial. Estimates suggest the industry could generate approximately €60 million in its first year of production, with long-term projections exceeding €1.2 billion over the next decade. Companies like Curity Pharma and Tikun Olam Europe are leading this transformation, attracting foreign investment and creating new job opportunities.
Greece’s Position in the Global Cannabis Industry
With Curity Pharma now operational and Tikun Olam Europe pioneering medical cannabis exports, Greece is quickly establishing itself as a key player in the global cannabis industry. The country’s favorable climate, strategic geographic position, and progressive policies make it an attractive destination for investment and expansion.
As Greece continues to refine its medical cannabis framework, additional companies are expected to enter the market, further solidifying its reputation as a European hub for medical cannabis cultivation and export. The future of Greece’s medical cannabis industry looks bright, with increasing patient access, expanding economic benefits, and growing international recognition.
Looking Ahead
Curity Pharma’s licensing represents a significant milestone in Greece’s medical cannabis journey. With regulatory support, technological advancements, and increasing global demand, Greece is well-positioned to become a leader in the European medical cannabis market.
As more companies follow Curity Pharma’s lead, the industry’s impact on the Greek economy and healthcare system will continue to grow, offering new treatment options for patients while contributing to economic development. The future of medical cannabis in Greece has never been more promising.
